DOAC compared with warfarin for VTE in low weight patients: A retrospective cohort study conducted through the VENUS network

Direct oral anticoagulants (DOACs), including apixaban, dabigatran, edoxaban, and rivaroxaban, are approved for the treatment and prevention of venous thromboembolism (VTE) and have become first-line agents for most patients. While dose adjustments are not recommended for the initial treatment of VTE by manufacturers of apixaban, dabigatran and rivaroxaban, limited evidence exists for the safety and efficacy of DOACs compared with warfarin in low weight patients. Phase III trials of DOACs in VTE included few underweight patients and did not include analyses of low weight categories [1 –3].

Source: Thrombosis Research - July 11, 2023 Category: Hematology Authors: Karlyn A. Martin, Nicola Lancki, Lisa Baumann Kreuziger, Celina Li, M. Elaine Eyster, Kristen Sanfilippo, Scott C. Woller, Rachel P. Rosovsky Tags: Letter to the Editors-in-Chief Source Type: research